Year : 2012  |  Volume : 3  |  Issue : 4  |  Page : 353-355

Istaroxime: A rising star in acute heart failure

1 Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, Punjab, India
2 Department of Cardiology, Heartline, Panchkula, Haryana, India

Correspondence Address:
Suruchi Aditya
Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, Punjab
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0976-500X.103705

Rights and Permissions

Heart failure in India is a growing epidemic. Around 30 to 40% of patients die from heart failure within one year of receiving the diagnosis. Currently available inotropes have not only failed to show consistent results but are also associated with adverse outcomes. Istaroxime is a novel intravenous agent with luso-inotropic properties that acts by inhibition of Na + /K + adenosine triphosphatase and stimulation of sarco/ endoplasmic reticulum calcium ATPase isoform 2. In clinical studies, it significantly decreased left ventricular end diastolic pressure, pulmonary capillary wedge pressure, heart rate and increased systolic blood pressure and cardiac index with no change in neurohormones, renal function or troponin I. Istaroxime is a promising alternative for patients presenting with acute heart failure syndrome for whom the therapeutic options are currently limited.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded669    
    Comments [Add]    
    Cited by others 6    

Recommend this journal